Keystone Heart, Venus Medtech ink Asian TAVR stroke partnership deal

Keystone Heart and Chinese heart valve maker Venus Medtech said today they inked a partnership deal covering China and other Asian markets. Through the deal, the companies will provide Venus Medtech’s transcatheter aortic valve replacement system along with Keystone’s TriGuard cerebral embolic protection device. TriGuard is a cerebral embolic protection device designed to reduce the amount of embolic material entering blood circulation to the brain during TAVR procedures, by allowing blood to pass through while catching potentially dangerous embolic debris. “Providing brain protection for every TAVR patient will differentiate Venus Medtech and position them as a leader in structural heart therapies – underscoring its dedication to excellence and focus on patient safety. This partnership provides us the opportunity to make an impact in the fast growing structural heart space in an extraordinarily important geographic market,” Keystone Heart prez & CEO Chris Richardson said in a press release. Venus Medtech said that it is hopeful that its TAVR device will be the 1st device approved by China’s Food and Drug Adminstration for marketing in the region. “It is of utmost importance to us that our devices improve the quality life of the patients whom receive them. Our transcatheter heart valve systems offer patients life-saving support — and collaborating with Keystone Heart allows us the opportunity to reduce the risk of brain injur...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Cardiovascular Catheters Replacement Heart Valves Keystone Heart Venus Medtech Source Type: news